GlassScriptPhysician profile
David Aaron Hammer
NPI 1811307507
$1,812.98
in general payments reported to CMS, 2019-2025
18 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.00 · 2022: $137 · 2023: $280 · 2024: $829 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $242.31 | 2023-2025 | |
| Genentech USA, INC. | $229.78 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Ucb, INC. | $224.86 | 2021-2024 | Briviact, Fintepla |
| Sk Life Science, INC. | $209.98 | 2022-2025 | |
| Harmony Biosciences LLC | $176.54 | 2023-2024 | Wakix |
| Pfizer INC. | $120.11 | 2023-2025 | |
| Amgen INC. | $107.72 | 2022-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $95.44 | 2023-2025 | Soliris, Ultomiris |
| Neurelis, INC. | $78.78 | 2023-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $77.82 | 2023-2024 | |
| Livanova USA, INC. | $68.41 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Tg Therapeutics, INC. | $47.51 | 2024 | |
| Biogen, INC. | $26.39 | 2025 | Vumerity, Tysabri |
| Lundbeck LLC | $25.11 | 2025 | Vyepti |
| Acorda Therapeutics, INC | $23.92 | 2024 | Ampyra |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $23.50 | 2023 | Gamunex-C |
| Vanda Pharmaceuticals INC. | $20.88 | 2024 | Ponvory |
| Teva Pharmaceuticals USA, INC. | $13.92 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.